Can Aspirin Save You From Cancer or Heart Disease?

[IRON-GAME]

TweetIn people with pre-existing cardiovascular disease, it has long been well documented that long-term use of aspirin is an effective anti-platelet treatment that significantly reduces the risk of serious cardiovascular events (such as heart attacks and strokes) by 30% and cardiovascular death by 15%.[1, 2]

This benefit greatly exceeds the potential risk of increased bleeding events, which is a side effect of aspirin.[3] Therefore clinical guidelines recommend that people with cardiovascular disease take low dose aspirin (75 to 162 mg) daily to prevent recurrence of cardiovascular events.[4-6]

More recently, the use of aspirin in healthy people for prevention of cardiovascular disease, as well as cancer, has been getting more and more attention. However, research on prophylactic use of aspirin conflicting and clinical guidelines are contradictory. Here I will shed some light on new research to help you make an informed decision whether aspirin may protect you…

Aspirin as a prophylaxis in primary prevention (i.e. to keep healthy people healthy)

Discussions about prophylactic use of aspirin revolve around cardiovascular disease, and more recently cancer. Here I will be dealing with them separately. But first, let’s get a perspective on bleeding caused by aspirin.

Bleeding – the notorious side effect of aspirin

Aspirin is well known for increasing bleeding risk, especially gastro-intestinal (GI) bleeding.[3] Despite common concerns over GI and cerebral bleeding caused by aspirin, evidence from randomized trials and large population studies of people using aspirin prophylactically for many years suggest those concerns are blown out of proportion.[7]

A large meta-analysis of 18 studies using aspirin doses of 75 to 375 mg found that the mean number of extra upper gastrointestinal bleeding cases associated with low-dose aspirin use is 1.2 per 1000 patients per year.[8] However, when evaluating the relationship between aspirin use and bleeds, it is important to distinguish between bleeding in relation to short-term use of aspirin, as reported in most of the published trials, and bleeding in relation to long-term use.[7, 9] Shortly after start of prophylactic aspirin use, the risk of a GI bleeding is high but decreases thereafter.[10] An analysis of 17 randomized studies found that the risk of a bleed in the first month of aspirin use was increased by 4-fold, but fell thereafter.[11] Data from long-term studies shown that after 5 years of aspirin use there is no significant excess risk of bleeding.[9]

Although gastric and intestinal mucosal damage can be seen on endoscopic examination after short-term aspirin administration, this appears to improve during continuous aspirin use and can be explained by a gastric adaptation to continuous low-dose aspirin.[12] In contrast to ibuprofen and rofecoxib, low-dose aspirin (80 mg), when compared to placebo, appears not to cause stomach ulceration in people with a healthy GI system.[13] On the other hand, aspirin use in people with untreated stomach ulcer can increase bleeding risk 15-fold.[14]

The most serious bleeds are those that lead to death, and despite frequent comments to the contrary, there appears to be no valid evidence that fatal GI bleeds are increased by low-dose aspirin.[7] Support for this comes from the landmark Antithrombotic Trialists’ meta-analysis, where there were 9 fatal GI bleeds in patients on aspirin and 20 in those on placebo.[2] Deaths due to bleeding were 3.9 per 100,000 patients per year in in patients using aspirin vs. 5.1 per 100,000 per year in those on placebo.[15] In line with this, a recent analysis concluded that major bleeding events that are comparable in severity to cardiovascular disease or cancer, are infrequent in people using aspirin prophylactically.[16]

Aspirin for prevention of cardiovascular disease

Most people who use aspirin as a prophylaxis do so for cardiovascular disease prevention. In contrast to the consistent evidence supporting the use of aspirin in secondary prevention, aspirin prophylaxis for cardiovascular disease prevention is debated among researchers.




Older meta-analyses of studies on prophylactic aspirin use concluded that despite important reductions in heart-attacks and ischemic stroke, the benefits are in large part offset by increases in hemorrhagic stroke and major bleeding event.[23-27]

In contrast to this previously perceived uncertain net value, a more recent meta-analysis, which also specifically analyzed the benefit-risk ratio in men vs. women, and in diabetics, concluded:[28]

“The use of low-dose aspirin was beneficial for primary prevention of cardiovascular disease and the decision regarding an aspirin regimen should be made on an individual patient basis. The effects of aspirin therapy varied by sex and diabetes status. A clear benefit of aspirin in the primary prevention of cardiovascular disease in people with diabetes needs more trials.”

This meta-analysis found we found significant benefits of aspirin use vs. placebo; major cardiovascular event, heart attack and ischemic stroke were reduced by of 10, 14, and 14% in the overall population who used aspirin.[28] The effects of aspirin may vary by sex and diabetes status. Aspirin use was associated with a significant reduction in the risk of cardiovascular events in both sexes but different specific types of benefits; a reduction in heart attack among men and a reduction in ischemic stroke among women.[28] Aspirin had no significant effect on cardiovascular disease in the overall diabetic population, but was associated with a reduction in heart attack among men with diabetes.[28]

The range of aspirin dose varied from 75 to 650 mg/day in the studies included in this meta-analysis. Notably, it was found that risk reductions achieved with low aspirin doses (75 mg/day) were similar to those obtained with higher doses (650 mg/day).[28] It was also pointed out that although there was an increase in bleeding events, it is not sensible to conclude that the benefit of aspirin is always offset by the risk of bleeding; in fact, the results suggest that the benefit of reducing risk of ischemic stroke outweigh the harm hemorrhagic stroke.[28]

Also, it is important to underscore that the current guidelines listed in table 1 are based on clinical trials of aspirin use in primary prevention of cardiovascular disease, and thus only consider the benefits of a reduction in cardiovascular risk versus potential harms from bleeding.[17, 29] Aspirin’s potential as an anti-cancer prophylaxis is not taken into consideration.

Aspirin for prevention of cancer

Accumulating research supports use of aspirin for cancer prevention.[9, 30-35] The evidence for an anti-cancer effect of aspirin is strongest for colorectal cancer, but rapidly accumulating data supports that aspirin also offers protection against development and/or progression/severity (i.e. incidence and mortality) of other common cancers [36], such as breast cancer [37-41] and prostate cancer.[42-45]

Cancer is the second most common cause of premature death worldwide, after heart disease, and its prevalence is increasing because of the aging population, as well as an increasing prevalence of risk factors such as obesity and physical inactivity.[46] Every year, there are 1.5 million new cancer cases and 560 000 cancer deaths in the US.[47, 48] During a lifespan, 41% of the US population will develop cancer and 21% will die from cancer.[47]

In light of the high and rising burden of cancer, aspirin’s potential anti-cancer effects need to be taken into consideration when evaluating the risk-benefit of aspirin use. Daily low dose aspirin (as low as75 mg) reduces deaths due to several common cancers, both during and after the study completion, and benefit increases with duration of aspirin use.[30] Specifically, in long-term studies (4 years or more) investigating the use of aspirin for primary and secondary prevention of cardiovascular disease, when compared to placebo, aspirin reduced 20-year cancer mortality by 20-30%, due mainly to fewer deaths after completion of the trials.[30] This suggest that aspirin has a long-term carryover effect and that it may take a long time to see the full benefits of aspirin on cancer related outcomes.

Amore recent analysis of cancer outcomes included 77,549 patients (40,269 randomly assigned to aspirin and 3, 280 to placebo) from previous studies of aspirin use and prevention of cardiovascular disease.[9] After a minimum of 5 years of follow-up, it was found that aspirin groups had 12% fewer cancer deaths compared with placebo groups. In studies of daily low-dose aspirin in primary prevention (i.e. healthy people) aspirin reduced cancer incidence from 3 years onwards by 25%, in both men and women.[9]

Net benefit of aspirin when considering prevention of both cardiovascular disease and cancer

In light of the new research on aspirin and cancer, the latest risk-benefit analyses are more favorable than the ones that only consider cardiovascular disease.[17, 49] A recent study assessed the benefits and harms of prophylactic use of aspirin in the general population by summarizing data from the most recent systematic reviews on the effect of aspirin on site-specific cancer incidence and mortality, cardiovascular events and side effects.[50] It was found that the effects of aspirin on cancer are not apparent until at least 3 years after the start of use, and some benefits are sustained for several years after cessation in long-term users. No differences between low and standard doses of aspirin are observed, but there were no direct comparisons. Excess bleeding is the most important harm associated with aspirin use, and its risk and fatality rate increases with age. For average-risk individuals aged 50-65 years taking aspirin for 10 years, there would be a relative reduction of between 7% (women) and 9% (men) in the number of cancer, heart attack or stroke events over a 15-year period and an overall 4% reduction in all deaths over a 20-year period. It was concluded that prophylactic aspirin use for a minimum of 5 years at doses between 75 and 325 mg/day appears to have a favorable benefit-harm profile and that longer use is likely to have greater benefits.[50]

A benefit and cost-effectiveness analysis investigated whether including a cancer mortality-reducing effect influences which men would benefit from aspirin for primary prevention.[51] It was demonstrated that when this potential effect of aspirin on cancer mortality is included, aspirin becomes beneficial (and cost-effective) for a large group of middle-aged men at low heart disease risk who otherwise might not receive net benefit from taking aspirin.[51] This suggests that guidelines on aspiring use should include the cancer effect and reconsider their recommendations for primary prevention based on all beneficial effects of aspirin.

Another study analyzed the overall balance of risk and benefit of low-dose daily aspirin in primary prevention, by looking at the major cardiovascular events, incident cancer, and major extra-cranial bleeds, as well as the time course of onset of respective effect of aspirin.[9] Aspirin reduced the risk of the composite outcome of major vascular events, cancer, or fatal extra-cranial bleeds by 12% after a follow-up of up to 8 years. Surprisingly, the proportion of major extra-cranial bleeds that were fatal was lower in patients taken aspirin versus those taking placebo (3.9% vs. 11.3%). Notably, the reduced risk of major cardiovascular events on aspirin was initially offset by an increased risk of major bleeding, but effects on both of these two outcomes diminished with increasing follow-up, leaving only the reduced risk of cancer from 3 years onwards.[9]

This study is notable because it assessed how effects on all major outcomes (cardiovascular disease, cancer and bleeding) evolve with time after 5 years of follow-up, which has never been done before. Previous systematic reviews and analyses of the risks and benefits of aspirin have not considered effects of aspirin on cancer incidence, mortality, or non-vascular death together, and have assumed that the effects of aspirin on major cardiovascular and bleeding events will be independent of duration of aspirin use. This study, together with the previous study showing that aspirin reduces 20-year cancer mortality by 20-30% [30], suggest that extended use of aspirin is be safer than previously supposed and of value in prevention of cancer development and cancer deaths in the general population.

It should be underscored that when evaluating the risk-benefit balance with aspirin use, one needs to not only consider the incidence of benefits and harms, but also take into account their respective consequences. Any fatality is fatal, but it is quite clear that a non-fatal stroke or heart attack is more likely to result in long-term disability than a non-fatal bleed.

When should you NOT take aspirin?

Several prevalent conditions are potential contraindications for low-dose aspirin use. People who have or have had stomach ulcers should also be careful with aspirin (even low-dose regimens) because of aspirin’s potential negative gastric effects.[3, 8, 14, 52-54] Other factors the increase risk of upper gastrointestinal bleeding in people taking low-dose aspirin are Helicobacter pylori infection, alcohol, calcium channel blockers, older age and male sex (incidence of serious upper gastrointestinal bleeding/perforation is twice as high in men than in women).[14, 55, 56]

Those with arthritis, who are likely to take non-steroidal anti-inflammatory drugs (NSAIDs) for their condition, should not take aspirin due to potential harmful medication interactions.[57, 58] For example, compared with those who used aspirin alone, patients taking aspirin plus ibuprofen had a 73% increased risk of cardiovascular mortality and an almost 2-fold increased risk of all-cause mortality.[57] Likewise, another study in healthy people found that use of prophylactic aspirin together with frequent use of non-aspirin NSAIDs (4 times/week, including ibuprofen), was associated with a 2-fold increase risk of a first heart attack.[58] Thus, NSAIDs may counteract the cardio-protective effects of aspirin. In addition, risk of bleeding and/or stomach ulcer is particularly high in people who take non-aspirin NSAID together with aspirin.[10, 13, 52, 59]

What aspirin dose and form should you take?

Low-dose aspirin is in range of 75 mg/day to 150 mg/day, and is commonly the dose that is used for primary prevention of cardiovascular disease. Notably, the cardiovascular disease risk reduction achieved with low aspirin doses (75 mg/day) are similar to those obtained with higher doses (650 mg/day).[28] This may be because the successive daily administration of only 30 mg of aspirin is sufficient to result in virtually inactivation of platelet COX-1, and thus blockade of platelet thromboxane production (the substance made by platelets that causes blood clotting and constriction of blood vessels).[77] However, there is no study using the 30 mg dose.

For cancer prevention, daily aspirin doses as low as 75 mg have been demonstrated to be protective [30, 33, 60], but a larger dose between 300 to 650 mg per day may confer greater cancer protection.[17, 61-63] People who have a family history of cancer may want to try a minimum daily aspirin dose of 325 mg. However, it should be noted that the protective gastric adaptation to aspirin is delayed and/or less effective when higher aspirin doses are taken (such as those doses used for anti-inflammatory purposes).[12]

When it comes to cancer prevention, duration of use may be more important than the actual dose.[9, 33, 63]. This is not surprising, as for most cancers, the time from carcinogenesis to clinically detected disease is at least 10 years.[63]

What form of aspirin should you take? It is commonly believed that enteric-coated and buffered (effervescent) forms of aspirin are less likely to cause GI bleeding than plain aspirin tablets. A study that investigated this found that the risk for GI bleeding plain, enteric-coated, and buffered aspirin at average daily doses of 325 mg or less were comparable.[64] At doses greater than 325 mg, the relative risk was – counterintuitively – larger for buffered aspirin than plain aspirin (there were insufficient data to evaluate enteric-coated aspirin at this dose level).[64] Another study that compared enteric-coated aspirin and plain aspirin found that the risk of stomach bleeding and/or perforation was the same for both.[10] When comparing buffered aspirin with plain aspirin, buffered aspirin does not cause less gastrointestinal symptoms compared with plain aspirin.[65]

Summary

The latest research does support the use of low-dose aspirin for primary prevention of both cardiovascular disease and cancer, in both men and women. When seen in a long-term perspective, the benefits of aspirin prophylaxis does outweigh the potential harm from bleeding/stomach ulceration in the large majority of the general population. This can be summarized with the following bullet points:[66]

**For every 1666 treated with aspirin for 1 year for primary prevention of heart disease there would be one less cardiovascular event.
**For every 3333 people treated with aspirin for a year there would be one extra significant bleed.
**For every 29 people taking aspirin for around 5 years, 20 years later one death from cancer would be prevented.

Use the lowest effective daily dose of 75-150 mg for cardiovascular disease prevention, or if you have cancer running in your family, you may want to opt for at least 300 mg. Stick with plain aspirin, as enteric-coated and buffered form of aspirin – contrary to common belief – don’t seem to reduce gastrointestinal symptoms. And plain aspirin is cheaper.

[Smokey-McPot]

TweetGreat read

[guns01]

Tweetvery very good read. i saw on a doctors show one time about this very subject that using asprin is all about weighing the risk verses the benefits. they broke down the stomach and bleeding issues and all the other blah blah. what it came down to is the vast majority of people it can and will help as long as they dont have underlying stomach or kidney issues that they are unaware of

[jipped genes]

Tweetthanks, good read

[CtPress]

Tweetthere are some natural alternatives to aspirin like policosanol which wont cause bleeding or leaky gut. here is a study that compares 100mg aspirin to 100mg policosanol.

https://www.ncbi.nlm.nih.gov/pubmed/9425618